"label","uuid:ID","rationale","description","instanceType","id","name"
"","52430bbe-e9a1-4fab-99e1-3c62ea38e2c2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","StudyDesign","StudyDesign_1","Study Design 1"
